Janux Therapeutics, Inc.
NASDAQJanux Therapeutics heads into its May 8 Q1 print under a cloud of analyst capitulation that has reset price expectations dramatically lower — yet a still-sizeable short position and defensive options skew suggest investors are far from done with the debate. The sharpest story here is the analyst flight. Barclays downgraded JANX all the way from Overweight to Underweight on April…
Snapshot as of 23 Jun 2026
Janux Therapeutics heads into its May 8 Q1 print under a cloud of analyst capitulation that has reset price expectations dramatically lower — yet a still-sizeable short position and defensive options skew suggest…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for JANX — free to start on ORTEX.
Sign up for free →Open JANX on ORTEX